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Abstract
AIM
To evaluate thresholds for serum 25(OH)D concentrations 
in relation to death, kidney progression and hospitalization 
in non-dialysis chronic kidney disease (CKD) population.
METHODS
Four hundred and seventy non-dialysis 3-5 stage CKD 
patients participating in OSERCE-2 study, a prospective, 
multicenter, cohort study, were prospectively evaluated 
and categorized into 3 groups according to 25(OH)D 
levels at enrollment (less than 20 ng/mL, between 20 
and 29 ng/mL, and at or above 30 ng/mL), considering 
25(OH)D between 20 and 29 ng/mL as reference group. 
Association between 25(OH)D levels and death (primary 
outcome), and time to first hospitalization and renal 
progression (secondary outcomes) over a 3-year follow-
up, were assessed by Kaplan-Meier survival curves and 
Cox-proportional hazard models. To identify 25(OH)D 
levels at highest risk for outcomes, receiver operating 
characteristic (ROC) curves were performed.
RESULTS
Over 29 ± 12 mo of follow-up, 46 (10%) patients dead, 
156 (33%) showed kidney progression, and 126 (27%) 
were hospitalized. After multivariate adjustment, 25(OH)D 
< 20 ng/mL was an independent predictor of all-cause 
mortality (HR = 2.33; 95%CI: 1.10-4.91; P = 0.027) and 
kidney progression (HR = 2.46; 95%CI: 1.63-3.71; P < 
0.001), whereas the group with 25(OH)D at or above 
30 ng/mL did not have a different hazard for outcomes 
from the reference group. Hospitalization outcomes 
were predicted by 25(OH) levels (HR = 0.98; 95%CI: 
0.96-1.00; P = 0.027) in the unadjusted Cox proportional 
hazards model, but not after multivariate adjusting. ROC 
curves identified 25(OH)D levels at highest risk for death, 
kidney progression, and hospitalization, at 17.4 ng/mL 
[area under the curve (AUC) = 0.60; 95%CI: 0.52-0.69; 
P = 0.027], 18.6 ng/mL (AUC = 0.65; 95%CI: 0.60-0.71; 
P  < 0.001), and 19.0 ng/mL (AUC = 0.56; 95%CI: 
0.50-0.62; P = 0.048), respectively.
CONCLUSION
25(OH)D < 20 ng/mL was an independent predictor of 
death and progression in patients with stage 3-5 CKD, 
with no additional benefits when patients reached the 
levels at or above 30 ng/mL suggested as optimal by 
CKD guidelines. 
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Core tip: This study examines the prognosis value of 
25(OH)D levels on death, chronic kidney disease (CKD) 
progression, and hospitalization in a cohort of 3-5 stage 
CKD subjects not on dialysis. The main findings were 
the predictor value of vitamin D deficiency (< 20 ng/
mL), but not insufficiency (< 30 ng/mL), for the 3-year 
incidence of death and CKD progression, which remained 
significant after multivariate adjustments. These results 
could highlight the need for a revision of the current 
guidelines, which have defined optimal vitamin D status 
at ≥ 30 ng/mL based on levels required to suppress 
parathyroid hormone, as opposed to our study, which 
evaluates thresholds for serum 25(OH)D concentrations 
in relation to “hard” endpoints.
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INTRODUCTION
There is a high prevalence of vitamin D (VD) deficiency 
in all stages of chronic kidney disease (CKD)[1-5]. Obser-
vational studies in this population have shown that 
VD levels correlated with cardiovascular disease and 
markers of renal injury, including albuminuria[1,6], renal 
progression[4,6-8], vascular calcification[9,10], left ven-
tricular hypertrophy[9] and mortality[8,11-13]. Moreover, 
growing evidence supports a potential role for VD rece-
ptor activation in suppressing the renin-angiotensin 
system, reducing proteinuria and ameliorating kidney 
dysfunction[14-16], showing 25-hydroxyvitamin D [25(OH)D] 
as an attractive, cheap and feasible treatment target[17]. 
As a result of these findings, current guidelines have 
suggested VD supplementation in CKD patients[18-21], 
increasing VD supplementation rates among this po-
pulation[22].
Nevertheless, these recommendations are opinion 
based and the optimal VD levels as well as the upper safe 
limit of VD intakes remains controversial[23,24]. Based on 
the inverse relationship between serum concentrations of 
25(OH)D and parathyroid hormone (PTH), most current 
guidelines have defined VD deficiency and insufficiency, as 
a serum 25(OH)D level of < 20 ng/mL (50 nmol/L) and 
20-29 ng/mL (52-72 nmol/L) respectively[18,19], suggesting 
a serum concentration of 25(OH)D above 30-40 ng/mL 
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(75-100 nmol/L) to be desirable, levels at which PTH is 
suppressed to a minimum in its relation to 25(OH)D[25,26]. 
By contrast, the Institute of Medicine advocates VD 
repletion as a level of 20 ng/mL [27]. Determining the 
25(OH)D target level for optimal health is especially 
important in CKD population, where overuse of VD leads 
to hypercalcemia, hypercalciuria and hyperphosphatemia, 
which could predispose to vascular calcification, nephro­
lithiasis and reduced glomerular filtration rate[28-30]. All 
these data suggest an optimal level of VD exists that is 
neither too high nor too low[31].
Aware of the lack of evidence behind guidelines 
recommendations, and our concerns about VD over-
supplementation, encouraged us to investigate the optimal 
VD status in non-dialysis CKD patients. The aim of our 
study was to evaluate thresholds for serum 25(OH)D 
concentrations in relation to hard end-points such as 
death, kidney progression and hospitalization in this 
population.
MATERIALS AND METHODS
Study design and patient selection
OSERCE-2 was a 3-year follow-up prospective, obser-
vational, study which enrolled 742 adults with 3 to 5-stage 
CKD not on dialysis subjects attending 39 centres in 
Spain, to evaluate the effects of vascular calcifications and 
CKD-mineral bone disorders on mortality, hospitalization 
and kidney progression[32]. Inclusion criteria were age 
≥ 18 years and CKD Stages 3-5. Exclusion criteria 
were acute kidney injury, transplantation, hospitalization 
in the month previous to the enrollment, and severe 
comorbidity. In this post-hoc analysis of the OSERCE-2 
study, patients on current treatment with active VD 
(calcitriol, α-calcidol or paricalcitol) were also excluded, 
so 25(OH)D levels reflected the effect of the exposure to 
VD.
The study was reviewed and approved by the Dr 
Peset Hospital Research Ethics Committee. All study 
participants provided informed written consent prior to 
study enrollment.
Study protocol and baseline data
The study protocol of the OSERCE-2 study has been 
previously reported[32]. All patients were assessed at 
baseline for blood pressure measurement, lateral lumbar, 
pelvis and hands X-ray, an ankle brachial pressure index 
(ABPI) determination and laboratory blood sampling. 
All blood samples were analyzed in a central laboratory, 
including 25(OH)D, 1,25(OH)2 vitamin D, creatinine, 
calcium, phosphorus, intact PTH, albumin, and high-
sensitive C-reactive protein. 25(OH)D levels were assessed 
by radioimmunoassay (Biosource), which were transformed 
to the usual method of reference (DiaSorin Liaison 
chemiluminescent radioimmunoassay) for improving the 
comparability of the results, as previously described[32]. 
To study the renal progression, blood samples for 
determination of serum creatinine levels were obtained 
every 12 mo. Estimated glomerular filtration rate (eGFR) 
was calculated using the modification of diet in renal 
disease (MDRD) formula[33]. 
Outcomes
Deaths episodes (primary outcome), time to first hos­
pital admission and the appearance of a combined 
renal end­point, defined as a drop > 30% in eGFR, or 
beginning of renal replacement therapy (secondary 
outcomes), were prospectively gathered over a 3-year 
period[32]. 
Statistics analysis
Summary statistics were reported as frequencies or 
percentages, and as mean ± SD, for categorical and 
quantitative variables, respectively. Skewed quantitative 
variables were expressed as geometric mean (95%CI), 
after log transformation. Presence or absence of pro-
minent calcification for Adragao (AS) and Kauppila 
scores (KS) was reported as AS ≥ 3 and KS > 6, 
respectively.
Patients were classified further into 3 groups by 
25(OH)D level: < 20 ng/mL (deficiency), 20­29 ng/mL 
(insufficiency) and ≥ 30 ng/mL. Comparison of baseline 
characteristics in these 3 groups was assessed using 
one-way analysis of variance (ANOVA) for continuous 
variables, and χ 2 test for trend, for categorical vari-
ables. Analysis of variables independently related to 
25(OH)D levels was assessed by lineal regression 
model. To assess the relationship between the odds 
of VD deficiency and clinical and laboratory baseline 
characteristics, a stepwise binary logistic regression was 
performed between 25(OH)D level < 20 or ≥ 20 ng/
mL as dependent variables. PTH and 1,25(OH)D levels 
were considered as posterior variables to 25(OH)D 
levels and then they were not introduced in the models, 
to avoid an overadjustment bias. Twenty-four hours 
urine proteinuria was not included either because it was 
available in only 50% of the patients. 
Kaplan-Meier analysis and log-rank tests were 
used to estimate the effects of VD status on all-cause 
mortality, appearance of the composite renal end-
point, and hospitalizations. We then used univariate 
and multivariate Cox proportional hazard regression 
models to determine the association of VD levels with 
various pre-specified outcomes. Patients with 25(OH)D 
levels between 20 to 29 ng/mL were considered as 
reference group. Covariates significantly associated in 
the univariate analysis were entered (forward selection: 
Likelihood ratio) into the models. The relatively small 
number of deaths limited the list of adjustment variables 
that were included in the regression analyses. To identify 
VD levels at highest risk for outcomes, we performed a 
receiver operating characteristic (ROC) curve. The value 
associated with the highest accuracy was considered 
as the cut-off point for defining an increased risk of 
death, appearance of the composite renal endpoint, and 
hospitalization.
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Relationship between 25(OH)D levels and baseline 
characteristics
Linear correlation analysis showed significant correlation 
between 25(OH)D levels and eGFR (R = 0.10; P = 0.027), 
body mass index (R = ­0.10; P = 0.046), serum levels 
of albumin (R = 0.10; P = 0.027), calcium (R = 0.12; P 
= 0.013), 1,25(OH)2 vitamin D (R = 0.20; P < 0.001), 
PTH (R = ­0.26; P < 0.001), and hemoglobin (R = 0.13; 
P = 0.005), proteinuria (log transformed, R = ­0.19; P 
= 0.004) and ABPI (R = 0.15; P = 0.002). Multivariate 
binary logistic regression analysis showed as independent 
predictors of 25(OH) < 20 ng/mL the albumin levels (OR 
= 0.61; 95%CI: 0.40­0.92; P = 0.018), the ABPI (OR 
= 0.28; 95%CI: 0.11­0.73; P = 0.010), and treatment 
with native VD (OR = 0.35; 95%CI: 0.17­0.73; P = 
0.005), and diuretics (OR = 2.03; 95%CI: 1.35­3.06; P 
= 0.001). 
Mortality 
Forty­six (10%) patients died after a mean follow­up 
of 29 ± 12 mo. Cardiovascular disease (n = 16, 35%) 
and infections (n = 8, 17%) were the most common 
causes of death. Tumors and others accounted for 11% 
(n = 5) and 13% (n = 6) of deaths, respectively. In 11 
cases (24%) the cause of death was not identified. The 
Kaplan­Meier survival analysis (Figure 2A) suggested 
that patients with 25(OH)D less than 20 ng/mL had 
significantly higher mortality than the other two groups 
(log rank test, P = 0.031). Univariate Cox regression 
found a more than twice higher risk of death in the group 
with the 25(OH)D level less than 20 ng/mL compared 
with the reference group (HR = 2.47; 95%CI: 1.18­5.18; 
P = 0.017), whereas the group with 25(OH)D at or 
above 30 ng/mL was not significantly different from that 
with the 25(OH)D between 20 to 29 ng/mL (HR = 0.78; 
95%CI: 0.26­2.32; P = 0.650). Multivariate analysis 
The literature indicates that annual mortality in 
patients with stage 3 to 5 CKD (not on dialysis), is 
between 3% and 9%. Previous studies have shown a 
35% prevalence of VD deficiency in this population[3]. 
Compared with the group with VD deficiency, the 
group with VD insufficiency shows a 57% decrease in 
mortality[8]. With 470 patients included, a minimum 
follow-up of three years, and considering an error of 
alfa = 0.05, the power estimation of the study is 0.754. 
The statistical methods of this study were reviewed 
by MD Molina, from the Department of Mathematics, 
Universidad de Alicante, Spain, who was included as 
a co-author. All data analyses were conducted using 
SPSS, version 15.0 (SPSS Inc., Chicago, IL). A P-value 
< 0.05 was considered statistically significant. 
RESULTS
Baseline data 
From the 742 subjects enrolled at OSERCE­2 Study, 252 
were excluded and 20 were lost to follow-up, leaving 
470 patients in the final analysis (Figure 1). Tables 1 
and 2 show the patient characteristics and laboratory 
values, respectively, as a function of vitamin D status. 
According to 25(OH)D levels, the proportion of patients 
with deficiency or insufficiency was 53% and 33%, 
respectively. At baseline, the proportion of patients with 
5-stage CKD, diabetes mellitus, diabetic nephropathy 
and chronic heart failure was higher in the group with 
less 25(OH)D levels. ABPI, eGFR, PTH, 1,25(OH)2 
vitamin D and albumin levels were increased in groups 
with better VD status, which showed lower degree of 
proteinuria. The group with 25(OH)D less than 20 ng/mL 
was prescribed more frequently treatment with diuretics 
and erythropoietin-stimulating agents, with a lower 
proportion of patients under native VD treatment. 
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Oserce 2 study
Stage 3-5 CKD patients enrolled 
at Oserce 2 study (n  = 742) 
(April 2009-May 2009)
Excluded (n  = 252)
  Treatment with active vitamin D or analogs (n  = 190) 
  Treatment data no available (n  = 47)
  Patients with 25(OH)D levels no measured  (n  = 15)
Stage 3-5 CKD patients without 
active vitamin D (n  = 490)
Lost to follow-up (n  = 20)
Stage 3-5 CKD patients 
included in the analysis 
(n  = 470)
3-year follow-up
Analysis
Figure 1  Flow diagram of patient selection for analysis. 
CKD: Chronic kidney disease; 25(OH)D: 25-hydroxivitamin D. 
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showed the predictive value of 25(OH)D levels as a 
continuous variable for preventing death when adjusted 
for multiple covariates in different models (Table 3). 
Adjusted for age, comorbidity, diabetes mellitus, eGFR 
and phosphorous and albumin levels, the HR for all-cause 
mortality for 25(OH)D < 20 vs 20­29 was 2.33 (95%CI: 
1.10­4.91; P = 0.027; Figure 3). The 25(OH)D ≥ 30 
group did not have a significantly different mortality 
hazard from the reference group (HR = 1.19; 95%CI: 
0.37­3.81; P = 0.775).
Progression of CKD and renal replacement therapy 
initiation
During the follow­up, 81 (17%) patients started renal 
replacement therapy and 156 (33%) patients showed 
the composite renal end-point. Kaplan-Meier analysis 
(Figure 2B) showed that the 25(OH)D < 20 group had 
significantly more risk than the other two groups (log 
rank test, P < 0.001). Univariate Cox regression found 
again higher risk of the renal end-point with 25(OH)D 
level less than 20 ng/mL compared with 20 to 29 ng/mL 
(HR = 2.78; 95%CI: 1.84­4.16; P < 0.001), whereas 
the group with 25(OH)D above 30 ng/mL did not show 
different risk from reference group (HR = 1.13; 95%CI: 
0.59­2.13; P = 0.717). Multivariate analysis showed the 
predictive value of VD levels as a continuous variable 
for preventing appearance of renal end point when 
adjusted for multiple covariates (Table 4). Adjusted for 
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Table 1  Baseline patient characteristics (n  = 470), as a function of vitamin D status
All 25(OH)D < 20 ng/mL 25(OH)D 20-29 ng/mL 25(OH)D ≥ 30 ng/mL P
n 470 252 (53%) 154 (33%) 64 (14%)
Age (yr)   66.1 ± 12.9   65.8 ± 13.1   65.9 ± 11.9   68.1 ± 12.1 0.421
Male sex (%) 309 (66%) 162 (64%) 101 (66%) 46 (72%) 0.303
High blood pressure (%) 444 (95%) 242 (96%) 144 (94%) 58 (91%) 0.072
Dyslipidemia (%) 311 (66%) 168 (68%) 101 (66%) 42 (66%) 0.646
Diabetes mellitus (%) 183 (39%) 114 (45%)   53 (34%) 16 (25%) 0.001
Ischemic heart disease (%) 104 (22%)   60 (24%)   33 (22%) 11 (17%) 0.224
Chronic heart failure (%) 43 (9%)   33 (13%)   7 (5%) 3 (5%) 0.005
Stroke (%)  52 (11%)   30 (12%)   15 (10%)   7 (11%) 0.668
Peripheral arterial disease (%)  93 (20%)   59 (24%)   22 (14%) 12 (19%) 0.117
Stage of CKD (%)
  3 (eGFR = 30-59 mL/min per 1.73 m2) 221 (47%) 103 (41%)   84 (54%) 34 (53%) 0.002
  4 (eGFR = 15-29 mL/min per 1.73 m2) 205 (44%) 105 (46%)   64 (42%) 26 (41%)
  5 (eGFR < 15 mL/min per 1.73 m2) 44 (9%)   34 (13%)   6 (4%) 4 (6%)
Etiology of CKD (%) 
  Hypertension 108 (23%)   54 (21%)   40 (26%) 14 (22%) 0.039
  Diabetes mellitus 108 (23%)   72 (29%)   29 (19%)   7 (11%)
  Tubulointerstitial disease   65 (14%)   24 (10%)   25 (16%) 16 (25%)
  Glomerulonephritis   47 (10%)   26 (10%)   15 (10%)   6 (10%)  
  Unknown/others 142 (30%)   75 (30%)   44 (29%) 20 (32%)
Smoking (%)1
  Never 231 (53%) 124 (52%)   82 (58%) 25 (44%) 0.494
  Ex-smoker 144 (33%)   81 (34%)   44 (31%) 19 (33%)
  Active   64 (14%)   35 (14%)   16 (11%) 13 (23%)
Blood pressure (kPa)
  Systolic 19.0 ± 2.9 19.3 ± 2.9 18.6 ± 2.8 19.0 ± 3.1 0.085
  Diastolic 10.2 ± 1.5 10.2 ± 1.6 10.1 ± 1.4 10.3 ± 1.7 0.617
Pulse pressure (kPa)   8.8 ± 2.5   9.1 ± 2.5   8.5 ± 2.5   8.7 ± 2.5 0.098
Body mass index (kg/m2) 28.6 ± 5.1 28.8 ± 5.5 28.6 ± 4.6 27.7 ± 4.4 0.294
  Underweight (≤ 18.5)   6 (1%)   4 (2%)   1 (1%) 1 (2%) 0.353
  Normal (18.6-24.9)   96 (20%)   50 (20%)   30 (19%) 16 (25%)
  Overweight (25.0-29.9) 210 (45%) 111 (44%)   68 (44%) 31 (48%)
  Obesity (> 29.9) 158 (34%)    87 (34%)   55 (36%) 16 (25%)
Waist (cm)
  Males 102.2 ± 12.0 102.1 ± 13.0 102.2 ± 10.6 102.4 ± 11.5 0.989
  Females   97.8 ± 13.5   98.3 ± 14.7   97.7 ± 12.2   95.7 ± 11.4 0.760
ABPI   1.01 ± 0.21   0.98 ± 0.20   1.04 ± 0.21   1.05 ± 0.22 0.013
Abnormal ABPI2 194 (41%) 100 (41%)   66 (44%) 28 (44%) 0.539
Abnormal Kauppila score3 107 (29%)   52 (27%)   35 (29%) 20 (36%) 0.183
Abnormal Adragao score4 121 (32%)   66 (33%)   38 (30%) 17 (29%) 0.474
Vitamin D supplementation (%) 43 (9%)  16 (6%)   17 (11%) 10 (16%) 0.012
Use of phosphate binders (%)   72 (15%)   47 (19%)   16 (11%)   9 (14%) 0.105
Use of ACEI/ARB (%) 365 (78%) 196 (79%) 121 (82%) 48 (76%) 0.947
Use of diuretic (%) 287 (61%) 173 (70%)   88 (58%) 26 (42%) < 0.001
Use of ESA (%) 124 (26%)   77 (31%)   31 (20%) 16 (25%) 0.015
1Data available in 439 patientes; 2< 0.9 or > 1.3; 3> 6 data available in 370 patients; 4≥ 3 data available in 383 patients. If not indicated otherwise, results are 
presented as mean ± SD, or number (percent). ABPI: Ankle-brachial pressure index; ACEI: Angiotensin-converting-enzyme inhibitor; ARB: Angiotensin II 
receptor blocker; eGFR: Estimated glomerular filtration rate; ESA: Erythropoietin-Stimulating agents; 25(OH)D: 25-hydroxivitamin D. 
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age, gender, diabetes mellitus, eGFR, and phosphorous 
levels, the HR for the composite renal end-point for the 
25(OH)D < 20 group compared to the reference group 
was 2.46 (95%CI: 1.63­3.71; P < 0.001; Figure 4). 
The 25(OH)D ≥ 30 group did not have a significantly 
different hazard for kidney progression from the 
reference group (HR = 1.20; 95%CI: 0.62­2.32; P = 
0.581).
Hospitalization
During the follow­up, 126 (27%) patients were ad­
mitted for hospitalization, cardiovascular (49%) and 
infections (20%) being the most common causes. 
Kaplan­Meier analysis (Figure 2C) indicated that crude 
hospitalization event-free period was different between 
the VD groups (log rank test, P = 0.039). Univariate 
Cox regression found a shorter hospitalization event-
free period in patients with 25(OH)D level less than 
20 ng/mL compared with 20­29 ng/mL (HR = 1.58; 
95%CI: 1.05­2.36; P = 0.027), with no difference 
between the 25(OH)D ≥ 30 and the reference groups 
(P = 0.861). Hospitalization outcomes were predicted 
by 25(OH) levels (HR = 0.98; 95%CI: 0.96­1.00; P 
= 0.027) in the unadjusted Cox proportional hazards 
model, but not after adjusting for age, eGFR, diabetes 
and comorbidity.
Cutoff points to define VD sufficiency based on hard 
endpoints
ROC curves identified VD levels at highest risk for death, 
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Table 2  Baseline laboratory values, as a function of vitamin D status
All (n  = 470) 25(OH)D < 20 ng/mL 
(n  = 252)
25(OH)D 20-29 ng/mL 
(n  = 154)
25(OH)D ≥ 30 ng/mL 
(n  = 64)
P
25-hydroxivitamin D (nmol/L)   52 ± 21 36 ± 9 61 ± 7   90 ± 16 < 0.001
1,25(OH)2 vitamin D (pmol/L) 103 ± 28   97 ± 27 111 ± 28 107 ± 23 < 0.001
Caalb (mmol/L)   2.40 ± 0.20   2.40 ± 0.15   2.42 ± 0.23   2.45 ± 0.23    0.163
P (mmol/L)   1.10 ± 0.26   1.10 ± 0.26   1.10 ± 0.26   1.07 ± 0.26    0.517
iPTH (ng/L)1 91 (85-97) 106 (96-116) 81 (73-91) 64 (55-74) < 0.001
Creatinine (μmol/L) 221 ± 97   239 ± 106 212 ± 88 212 ± 88    0.017
eGFR (MDRD, mL/min per 1.73 m2)   29.4 ± 11.5   28.1 ± 11.9   30.8 ± 10.8   30.5 ± 11.1    0.049
Urine protein excretion (g/24 h)1,2   0.592 (0.502-0.697)   0.699 (0.573-0.853)   0.448 (0.321-0.626)   0.448 (0.271-0.742)    0.034
hsCRP (nmol/L)1 36.2 (29.5-39.1) 37.1 (33.3-41.0) 36.2 (31.4-41.0) 32.4 (26.7-39.1)    0.506
Albumin (g/L) 40 ± 5 39 ± 5 41 ± 5 40 ± 5    0.011
Total proteins (g/L)   77 ± 12   77 ± 11   77 ± 13   76 ± 14    0.877
Total cholesterol (mmol/L)   4.7 ± 1.1   4.7 ± 1.1   4.7 ± 1.0   4.8 ± 1.1    0.603
HDL cholesterol (mmol/L)   1.3 ± 0.4   1.3 ± 0.3   1.3 ± 0.4   1.3 ± 0.4    0.973
LDL cholesterol (mmol/L)   2.7 ± 0.9   2.7 ± 0.9   2.7 ± 0.9   2.9 ± 0.8    0.344
Hemoglobin (g/L) 130 ± 16 129 ± 16 132 ± 16 132 ± 18    0.058
Ferritin (pmol/L)1 225 (207-245) 227 (202-252) 216 (187-252) 247 (191-319)    0.635
Transferrin (μmol/L)   3.0 ± 1.2   2.9 ± 1.2   3.0 ± 1.2   3.1 ± 1.3    0.289
Glucose (mmol/L)   6.3 ± 2.2   6.3 ± 2.3   6.4 ± 2.4   5.9 ± 1.5    0.241
124 h urine proteinuria obtained in 237 (50%) patients; 2Skewed values are presented as geometric mean with 95%CI. Caalb: Calcium adjusted for albumin 
levels; eGFR: Estimated glomerular filtration rate; HSCRP: High-sensitive C reactive protein; iPTH: Intact parathyroid hormone; MDRD: Modification of 
diet in renal disease; P: Phosphorous; 25(OH)D: 25-hydroxivitamin D. If not indicated otherwise, results are presented as mean ± SD.
Table 3  Adjusted Cox proportional hazards models of patient survival (events = 46)
Model Covariates controlled for Adjusted HR (95%CI) P
0 (Unadjusted) 25-hydroxivitamin D levels (mg/dL) 0.95 (0.91-0.99)   0.009
1 25-hydroxivitamin D levels (mg/dL) + age 0.95 (0.91-0.99)   0.009
2 Model 1 + diabetes mellitus, ischemic heart disease, chronic heart failure 0.96 (0.92-0.99)   0.028
3 Model 1 + peripheral arterial disease, abnormal ABPI1, phosphorous (mg/dL) 0.95 (0.92-0.99)   0.023
4 Model 1 + DBP (mm Hg), 1,25(OH)2 vitamin D (pg/mL), estimated GFR (mL/min per 1.73 m2) 0.96 (0.92-0.99)   0.020
5 Model 1 + vascular calcification [Kauppila score (log), Adragao score (log)], CKD stage 5 0.95 (0.91-1.00)   0.050
6 Model 1 + obesity, hemoglobin (g/L), albumin (g/dL) 0.95 (0.92-0.99)   0.019
1< 0.9 or >1.3. ABPI: Ankle-brachial pressure index; DBP: Diastolic blood pressure; GFR: Glomerular filtration rate.
Table 4  Multivariate Cox regression analysis in relation to 
renal end point (events = 156)
HR (95%CI) P  value
25-hydroxivitamin D (ng/mL) 0.97 (0.95-0.99)    0.004
Age (yr) 0.99 (0.97-1.00)    0.044
Male sex 2.20 (1.47-3.30) < 0.001
Estimated GFR (mL/min per 1.73 m2) 0.93 (0.91-0.95) < 0.001
ABPI (mmHg) 0.23 (0.10-0.53)    0.001
Hemoglobin (g/L) 0.84 (0.78-0.94)    0.001
ABPI: Ankle-brachial pressure index; GFR: Glomerular filtration rate.
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the composite renal endpoint, and hospitalization, 
at 17.4 ng/mL [area under the curve (AUC) = 0.60; 
95%CI: 0.52­0.69; P = 0.027], 18.6 (AUC = 0.65; 
95%CI: 0.60­0.71; P < 0.001), and 19.0 (AUC = 0.56; 
95%CI: 0.50­0.62; P = 0.048), respectively. 
DISCUSSION
One of the main limitations for the development of 
evidence-based clinical recommendations for VD 
supplementation lies in the discrepancies in the criteria 
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Figure 2  Kaplan-Meier survival (A), and appearance of the composite renal endpoint (B) and the hospitalization (C) curves as a function of 
25-hydroxyvitamin D levels (< 20 ng/mL, 20-29 ng/mL and ≥ 30 ng/mL).
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Figure 3  Proportion of patients with different 25-hydroxyvitamin D levels and hazard ratio (95%CI) for mortality after adjustment by age, comorbidity, 
diabetes mellitus, estimated glomerular filtration rate and albumin levels. 25(OH)D: 25-hydroxivitamin D.
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for defining VD deficiency and insufficiency, which can 
explain conflicting results from meta­analysis addressing 
vitamin D levels and outcomes[24,34]. These criteria vary 
among authors and societies, including 25(OH)D levels 
below which osteomalacia [10 ng/mL (25 nmol/L)] 
or secondary hyperparathyroidism [20-30 ng/mL (50 
to 75 nmol/L)] may appear[18-20,35,36]. Being aware of 
their potential clinical significance, the present study 
examines the prognosis value of 25(OH)D levels in a 
cohort of 3-5 stage CKD subjects not on dialysis, trying 
to identify cut-off points for serum 25(OH)D levels to 
define VD sufficiency. These cut­offs were not based on 
biological abnormalities as classically noted[25,26], but on 
VD levels at highest risk for death, CKD progression and 
all-cause hospitalization. 
Although randomized clinical trials are the best way 
for generating a high evidence for treatment decisions, 
trials are rare and suboptimal in nephrology[37]. There-
fore, observational studies have an important role, 
particularly when the intervention, in this case vitamin 
D supplementation, is inexpensive and potentially eff-
ective. Although there are previous prospective obser-
vational studies which examined the prognosis value of 
25(OH)D levels in CKD subjects not on dialysis[8,12], this 
is the first one, to our knowledge, in which 25OH(D) 
levels unequivocally reflect exposure to VD, given that 
patients on treatment with active VD were excluded, as 
well as including the biggest cohort of non-dialysis CKD 
subjects with data regarding emerging cardiovascular 
risk factors as vascular calcification scores and ABPI. 
In the main analysis of the OSERCE-2 study, low VD 
levels were associated to worse survival and CKD pro-
gression only in the univariate analysis[32]. However, 
26% of patients of the study received activated VD, 
which may confer a protective effect and therefore may 
decrease any negative effect of VD levels observed, 
as it has been stated on dialysis population[38]. In this 
context, we conducted this post-hoc analysis of the 
OSERCE-2 dataset in patients without active VD 
treatment. In this selected cohort, the main findings 
were the independent predictor value of VD deficiency, 
but not insufficiency, for the 3­year incidence of death 
and CKD progression, which remained significant after 
multivariate adjustments, as previously published[8,12]. 
In a prospective study involving 94 CKD patients, 
those with 25(OH)D levels less than 16.7 ng/mL had 
a higher mortality rate[12]. 25(OH)D was confirmed as 
an independent inverse predictor of death in a 6-year 
follow-up study which included 168 CKD subjects[8]. 
In that study patients with ≥ 15 ng/mL of 25(OH)D 
showed a reduction in mortality by 33% to 60% in the 
different models, compared to patients with 25(OH)D 
< 15 ng/mL. Less CKD progression to end-stage renal 
disease was also reported in the groups of patients 
with better VD status. All these data are in agreement 
with our results, which show how low 25(OH)D levels 
predicted mortality and CKD progression independently 
of such traditional and non-traditional risk factors, as 
vascular calcification or inflammation. In this context, 
it is noteworthy that the lack of association between 
25(OH)D levels and vascular calcification observed 
in our study, is in agreement with some[12], but not 
all[9,10], previously published data. These findings indi-
cate that 25(OH)D may impact on CKD outcomes by 
additional mechanisms including the suppression of 
the renin-angiotensin system, albuminuria reduction 
or amelioration of left ventricular hypertrophy[6,9,16,31,39]. 
Of note, we have detected ABPI as an independent 
predictor of VD deficiency, which could contribute to 
vascular stiffness and high cardiovascular risk for this 
population. 
More interestingly, our study, as the first prospective 
which analyzed the upper level associated to better 
improvement in survival and CKD progression on CKD 
patients, did not demonstrate additional benefits on 
these hard outcomes when patients reached the optimal 
target levels for VD suggested by current guidelines (≥ 
30 ng/mL). It is noteworthy that all three cut-off points 
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Figure 4  Proportion of patients with different 25-hydroxyvitamin D levels and hazard ratio (95%CI) for composite renal end-point after adjustment by age, 
sex, diabetes mellitus, estimated glomerular filtration rate and albumin levels. 25(OH)D: 25-hydroxivitamin D.
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for serum 25(OH)D levels at highest risk for death, CKD 
progression and all-cause hospitalization were between 
17 ng/mL and 19, which reinforces the threshold value 
for abnormally reduced 25(OH)D in 20 ng/mL. These 
findings confirm the data reported in the biggest retro­
spective observational study analyzing VD and mortality 
in CKD patients. Navaneethan et al[40] studied 12763 
patients with 3-4 stage CKD, showing 25(OH)D level ≤ 
15 ng/mL to be associated independently with a 33% 
increased risk of all-cause mortality, whereas the group 
with 25(OH)D levels of 15-29 ng/mL did not show a 
significantly increased risk of mortality compared with 
patients with 25(OH)D levels ≥ 30 ng/mL. 
Taking all these data together, we agree with the 
Institute of Medicine recommendation to consider 
sufficient 25(OH)D levels of at least 20 ng/mL, given 
that serum 25(OH)D concentrations above 30 ng/
mL are not consistently associated with increased 
benefit[27,40]. In addition, most clinical trials have only 
confirmed the neutral effect of VD supplementation on 
hard outcomes[41], whereas some controlled studies 
have shown positive results in spite of the mean VD 
concentration not reaching the optimal recommended 
levels of ≥ 30 ng/mL[16]. Moreover, VD might not be 
safe in all settings, and supplementing could cause harm 
in people with CKD, who have a high prevalence of 
vascular calcification, and a decreasing ability for renal 
excretion of calcium and phosphorous[32,42]. Excessive VD 
supplementation may be particularly harmful in those 
high risk individuals with serum 25(OH)D levels above 
20 ng/mL which are classified as insufficient according 
to current guidelines, and who then are treated with 
high-dose supplements of VD containing many times 
the levels of intake recommended for adults (600-800 
UI/d)[18,27,43]. Although some experts suggest that it is 
safe to carry higher vitamin D levels (40-70 ng/mL), this 
recommendation is based on acute and not long-term 
observations[44]. 
Lastly, our study confirmed the high prevalence 
of low VD status on CKD patients[1-5]. There are many 
factors which could contribute to the deficiency that are 
not related to GFR, including limited exposure to the sun, 
reduced dietary intake and urinary loss of 25(OH)D and 
VD-binding protein in proteinuric nephropathies[24,44,45]. 
The present study, as others[8,12,38], has shown significant 
correlation between 25(OH)D levels and body mass index 
and albumin, which emphasizes the relationship between 
nutritional status, VD levels and survival in chronic 
illness as CKD. Of note, the independent relationship 
observed, even after adjustment for chronic heart failure, 
between VD deficiency and diuretic use. VD deficiency 
is highly prevalent in heart failure patients, being a 
significant predictor of reduced survival. In addition, loop 
diuretics treatment may worsen osteoporosis on general 
population, but no data are available in CKD patients[46,47].
Strengths and limitations
The strong points of the study include the relatively 
high number of patients included and the 3-year follow-
up, which strengthens the study’s power. To minimize 
the inter-method and seasonal variability in VD and 
PTH measurements, blood samples were analyzed by a 
central laboratory, and patients’ recruitment was done 
in a short period of time (April-May)[32]. In contrast, 
there are several limitations to be commented. As a 
longitudinal study, it is still insufficient to determine 
whether the association between low 25(OH)D levels 
and worse CKD outcomes is causal and reversible, which 
should be tested in future randomized clinical trials. The 
results may not be valid to non-Caucasian populations 
living at other latitudes, or to patients on active VD 
treatment. The multivariate analysis of cardiovascular 
deaths was limited due to its low incidence. Lastly, it 
would be interesting to study other relevant bone-related 
clinical outcomes, such as bone-density changes or 
fracture risk. 
In conclusion, in accordance with previously pub-
lished data, the present study confirms: (1) a high 
prevalence of 25(OH)D deficiency and insufficiency 
in non­dialysis CKD patients; and (2) an independent 
association between serum 25(OH)D levels and worse 
clinical outcomes, such as death and CKD progression. 
The results of this study add to the knowledge of optimal 
VD status in non-dialysis CKD patients, identifying the 
threshold value for abnormally reduced 25(OH)D in 
20 ng/mL, which is in agreement with the Institute of 
Medicine recommendations. Whereas high doses of 
VD supplementation on this population can lead to a 
calcium and phosphate overload, promoting vascular 
calcification and CKD progression, our results suggest 
that, with the limitations inherent to the observational 
studies, 25(OH)D levels between 20 to 30 ng/mL could 
be sufficient for CKD patients. Randomized clinical trials 
are warranted to know the most favorable 25(OH)D level 
for CKD patients. 
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(PTH), clinical guidelines most commonly recommend a serum concentration 
of 25(OH)D above 30-40 ng/mL (75-100 nmol/L), levels at which PTH is 
suppressed to a minimum in its relation to 25(OH)D. However, there is a 
lack of evidence regarding this target recommendation, and overuse of VD 
supplementation on this population can lead to a calcium and phosphate 
overload, promoting vascular calcification and CKD progression. 
Innovations and breakthroughs
Being aware of both the therapeutic and iatrogenic power of VD supple-
mentation, the present study examines the prognosis value of 25(OH)D levels 
in a cohort of 3-5 stage CKD subjects not on dialysis, trying to identify cut-off 
points for serum 25(OH)D levels to define VD sufficiency. These cut-offs were 
not based on biochemical abnormalities as classically noted, but on VD levels 
at highest risk for death, CKD progression and all-cause hospitalization. The 
results of this study add to the knowledge of optimal VD status in non-dialysis 
CKD patients, identifying the threshold value for abnormally reduced 25(OH)D 
in 20 ng/mL. 
Applications
The data in this study suggested that the optimal VD level might be lower than 
is currently recommended, advocating that 25(OH)D levels at or above 20 ng/
mL could be sufficient for CKD patients. The authors recommend caution when 
nutritional VD is prescribed.
Terminology
25(OH)D, also known as calcifediol, is a prehormone that is produced in the 
liver by hydroxylation of vitamin D3 (cholecalciferol). Serum 25(OH)D levels are 
considered the best indicator of VD status.
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associated to better improvement in survival and CKD progression on CKD 
patients, did not demonstrate additional benefits on these hard outcomes 
when patients reached the optimal target levels for VD suggested by current 
guidelines (≥ 30 ng/mL).So with this study, despite the limitations, the authors 
provide a new option in this  so controversial field of VD treatment in CKD 
patients. 
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